Sareum Holdings PLC

Sareum Holdings PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)177.50
  • Today's Change10.00 / 5.97%
  • Shares traded183.30k
  • 1 Year change-47.41%
  • Beta-0.2233
Data delayed at least 20 minutes, as of Sep 23 2022 17:13 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Sareum Holdings PLC's revenues fell -100.00% from 47.20k to 0.00. has fallen 52.18% from a loss of 985.91k to a larger loss of 1.50m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-48.39%
Return on equity-51.44%
Return on investment-51.44%
More ▼

Cash flow in GBPView more

In 2021, Sareum Holdings PLC increased its cash reserves by 48.99%, or 883.30k. Cash Flow from Financing totalled 2.49m or -- of revenues. In addition the company used 1.57m for operations while cash used for investing totalled 37.86k.
Cash flow per share-0.0273
Price/Cash flow per share--
Book value per share0.0834
Tangible book value per share0.0834
More ▼

Balance sheet in GBPView more

Sareum Holdings PLC uses little or no debt in its capital structure.
Current ratio29.54
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in GBP

Year on year, growth in earnings per share excluding extraordinary items dropped -43.56%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.